Otolaryngology Doctors in Colonial Heights, VA Accepting Medicare

4 Otolaryngology doctors found. Showing 1 - 4

John L Ditto, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 241 Charles H Dimmock Pkwy Ste 6, Colonial Heights, VA 23834 Phone: 804-765-5320    Fax: 804-765-5325

Dr. Mayand Praful Vakil, MD Otolaryngology - Plastic Surgery within the Head & Neck Medicare: Medicare Enrolled Practice Location: 241 Charles H Dimmock Pkwy Ste 6, Colonial Heights, VA 23834 Phone: 804-765-5320    Fax: 804-805-2903

Sneh Lavingia, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 241 Charles H Dimmock Pkwy Ste 6, Colonial Heights, VA 23834 Phone: 804-765-5320    Fax: 804-765-5325

Dr. Tejas Harish Raval, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 241 Charles H Dimmock Pkwy Ste 6, Colonial Heights, VA 23834 Phone: 804-765-5320    Fax: 804-765-5325

News Archive

CDC completes a three-year study of best fire prevention practices in 10 nations

The U.S. Centers for Disease Control and Prevention (CDC) and System Planning Corporation's TriData division, which specializes in public safety research and consulting, recently completed a three-year study of best fire prevention practices in 10 nations.

Availability of alcohol to young adults may have large effects on risky behaviors

Results from a recent analysis reveal that the availability of alcohol associated with turning 21 years old may have relatively large effects on risky behaviors, especially in men. The findings are published in Contemporary Economic Policy.

Immune cell age plays role in retinal damage in age-related macular degeneration

Studying a mouse model of age-related macular degeneration, the leading cause of blindness in older Americans, scientists at Washington University School of Medicine in St. Louis have found age is key in determining whether damaging blood vessels will form beneath the retina and contribute to vision loss.

FDA grants orphan drug designation to Soligenix's SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

Read more Medical News

› Verified 6 days ago